|
- A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood . . . - PubMed
In this study, we demonstrate the biological outcome of BAFF blockade in cynomolgus monkeys using a soluble fusion protein consisting of human BR3 and human IgG1 Fc In vitro, BR3-Fc blocked BAFF-mediated survival and proliferation of cynomolgus monkey B cells
- A Soluble BAFF Antagonist, BR3-Fc, Decreases Peripheral Blood B Cells . . .
BR3-Fc Decreases CD20 + Follicular and Marginal Zone B Cells in Tissues Both BR3-Fc treatment groups showed a decrease in CD20 + follicular B cells in the spleen and LNs (axillary, mandibular, and mesenteric) compared with the control group (Tables 3 and 4)
- BAFF regulates activation of self‐reactive T cells through B‐cell . . .
Indeed, treatment of NOD mice with the BAFF-blocking compound, BR3-Fc, resulted in a delayed onset and reduced incidence of diabetes
- (PDF) Anti-BR3 antibodies: A new class of B-cell immunotherapy . . .
Comparative analysis of BR3-Fc and anti-BR3 mAb reveals a lower B-cell dependence for BAFF-mediated survival in nonhuman primates than in mice
- BAFF and APRIL support chronic lymphocytic leukemia B-cell survival . . .
Chronic lymphocytic leukemia (CLL) B cells express BR3, the specific receptor for the B cell–activating factor of tumor necrosis factor family (BAFF)
- Anti-BR3 antibodies – a new class of B cell . . . - Oxford Academic
The results from this study indicate that in mice anti-BR3 monoclonal antibody reduces B cells to a higher degree when compared to anti-CD20 or BAFF-blockade through BR3-Fc Anti-BR3 depletes B cells with a slower kinetics than anti-CD20 but showed high B cell depletion and a decrease in bone marrow plasma cells which was not seen with anti-CD20
- A Soluble BAFF Antagonist, BR3-Fc, Decreases Peripheral Blood B Cells . . .
The in vitro biological activity of BR3-Fc on cynomolgus monkey B cells was established in two different in vitro assays before in vivo administration In the CD40L BAFF-mediated B-cell survival assay, 24 B cells were isolated from cynomolgus monkey PBMCs and cultured with CD40L and IL-2 for 4 days
- Briobacept - an overview | ScienceDirect Topics
Briobacept (BR3-Fc) It is a recombinant glucoprotein formed by 2 molecules from the BLyS receptor (BR3) joined to the Fc domain of human IgG1 BR3-Fc binds BlyS (BAFF) but not APRIL
|
|
|